London, United Kingdom (PressExposure) January 17, 2012 -- Our exports estimated the global angina pectoris therapeutics market to be worth $9,655.4m in 2010. It is expected to grow to $12,707.4m by 2018 at a compound annual growth rate (CAGR) of 3.5%. This growth can be primarily attributed to the rise in the number of patients undergoing treatment for angina pectoris and the expected approval of novel therapies such as Generx and varespladib, which are currently in late stage clinical development. However, if approved, these products are expected to be marketed at a premium price by their innovator companies when compared to other treatment options for angina. The reason why the launch of such products is at premium prices is attributed to the novel mechanism of action of these products which leads to a marked improvement in efficacy and safety over the currently marketed products. As a result the market penetration of these products is expected to remain low, limiting the growth rate of the angina pectoris therapeutics market. The forecast period will also witness patent expiries of major marketed products such as Lipitor (atorvastatin) in 2011, Aggrastat (tirofiban) in 2012, Angiomax/Angiox (bivalirudin) in 2015 in Europe and Crestor (rosuvastatin) in 2016. Such patent expiry of the major marketed products will attract generic versions of these drugs to the market. Therefore the angina pectoris therapeutics market is expected to witness moderate growth with a significant number of generics playing a major role in the forecasted period, which is similar to the present market scenario.
GlobalData assessed the current competitive landscape for angina pectoris drugs and found that competition is weak. All the available treatment options are moderately successful in meeting the market demand. Although the market has various treatment options available, none of them is able to manage angina pectoris adequately. The products currently available in the market are associated with average efficacy and safety profiles.
In addition,the current treatment options offer poor quality of life due to their lack of efficacy in reducing cardiovascular events and mortality. As the products currently in the market do not serve the unmet need, the market continues to offer opportunities for products in the pipeline with novel mechanism of action and disease modifying characteristics. The unmet need in the angina pectoris therapeutics market is considered to be significant and can be fulfilled by technologically advanced products with improved safety and efficacy profiles
For Sample Pages, please click or add the below link to your browser:
GlobalData's research indicates that the angina pectoris therapeutics market pipeline is strong. There are 16 molecules in the pipeline across various phases of clinical development. GlobalData's analysis concludes that out of the 16 molecules in the pipeline, twelve molecules are first-in-class based on their unique or novel mechanism of action. Within the late stage of clinical development (Phase III), four molecules are considered to be of commercial importance to the market and are expected to have an impact in the forecast period. These are Generx, varespladib, rivaroxaban and otamixaban which are expected to influence the market growth within the forecast period, following their approval and subsequent launch.
GlobalData, the industry analysis specialist, has released its new report, "Angina Pectoris Therapeutics
- Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global angina pectoris therapeutics market and identifies the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global angina pectoris therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globalmarketsdirect.com/
For more details contact:
North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782